ArticleAACE endocrinology and diabetes
Romosozumab Treatment After Parathyroidectomy for Primary Hyperparathyroidism-Complicated Osteoporosis: A Two-Case Report.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Parathyroidectomy increases bone mineral density (BMD) by 3% to 4% in patients with primary hyperparathyroidism (PHPT); however, limited studies have demonstrated the effect of postoperative medical therapy, particularly with bisphosphonate and denosumab, on BMD. Herein, we report 2 cases of PHPT in which romosozumab, an antisclerostin antibody, increased BMD after parathyroidectomy. Case Report: Case 1. A 67-year-old woman was diagnosed with PHPT and advanced osteoporosis, with T-scores of -4.0 and -5.4 in the lumbar spine (LS) and distal radius (DR), respectively. After parathyroidectomy and 5-year treatment with eldecalcitol and raloxifene, T-scores were -3.3 and -5.6 in the LS and DR, respectively. Thereafter, 12-month romosozumab therapy with eldecalcitol increased BMD by 25.2% (0.717 to 0.898 g/cm Discussion: We present the first reported cases of PHPT-complicated osteoporosis in which BMD improved after romosozumab treatment markedly in the LS by 25% to 30%. These cases suggest that postoperative romosozumab therapy may be a potential therapeutic option in patients with PHPT and osteoporosis. Conclusion: Romosozumab may be a promising postoperative therapy for patients with PHPT and osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.